



# Curis

Lifesciences Ltd.

**CERTIFIED TRUE COPY OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF THE CURIS LIFESCIENCES LIMITED ON THURSDAY THE 15<sup>TH</sup> MAY, 2025 AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT PF-23, GIDC SANAND - II, INDUSTRIAL ESTATE, AHMEDABAD, SANAND, GUJARAT, INDIA, 382110 AT 11:00 A.M.**

**INITIAL PUBLIC OFFERING ("IPO") OF THE COMPANY BY FRESH ISSUE OF EQUITY SHARES:**

**"RESOLVED THAT** subject to the approval of the members of the Company, pursuant to the provisions of Sections 23 and 62(1)(c) and all other applicable provisions, if any, of the Companies Act, 2013, (hereinafter referred to as the "Act") (including any statutory modifications or re-enactment thereof for the time being in force), read with the Memorandum of Association and Articles of Association of the Company and the Listing Agreement to be entered into with the respective stock exchange, where the Company's equity shares are proposed to be listed and subject to the approval to the extent necessary of Securities and Exchange Board of India ("SEBI"), Reserve Bank of India ("RBI") and all other concerned statutory and other authorities, as may be required (hereinafter collectively referred to as "Appropriate Authority") and to the extent necessary, such other approvals, consents, permissions, sanctions and the like, as may be necessary, and subject to such conditions and modifications as may be prescribed, stipulated or imposed by any of them while granting such approvals, consents, permissions, sanctions and the like, which may be agreed to by the Board of Directors of the Company (hereinafter referred to as the "Board" which term shall include any Committee(s) constituted / to be constituted by the Board to exercise its powers including the powers conferred upon it), the approval of the Board of Directors of the Company be and is hereby accorded to create, offer, issue and allot equity shares of an aggregate number up to and not exceeding 22,50,000 (Twenty Two Lakhs Fifty Thousand) **Equity Shares (the "Fresh Issue")** at a price as may be decided by the Board of Directors in consultation with Book Running Lead Manager, ranking pari-passu with the existing equity shares of the Company, to such person or persons who may or may not be the shareholders of the Company as the Board may decide, including anchor investors, if any, one or more of the members of the Company, employees (through a reservation or otherwise), Hindu Undivided Families, foreign portfolio investors, venture capital funds, alternative investment funds, foreign venture capital investors, multilateral and bilateral financial institutions, non-resident Indians, state industrial development corporations, insurance companies, provident funds, pension funds, the National Investment Fund, insurance funds set up by army, navy, or air force of the Union of India, insurance funds set up and managed by the Department of

CIN No: U24230GJ2016PLC086559

PF-23 Sanand GIDC II, Sanand Ahmedabad-382110, Gujarat, India

Website: [www.curisls.com](http://www.curisls.com) | Email: [info@curisls.com](mailto:info@curisls.com) | Phone No: +91-7096558558



# Curis

Lifesciences Ltd.

Posts, India, trusts/societies registered under the Societies Registration Act, 1860, development financial institutions, systemically important non-banking financial companies, Indian mutual funds, members of group companies, Indian public, bodies corporate, companies (private or public) or other entities (whether incorporated or not), authorities, and to such other persons including high net worth individuals, retail individual bidders or other entities in one or more combinations thereof and/or any other category of investors as may be permitted to invest under Applicable Laws by way of initial public offering including General Public their friends, relatives and associates, foreign / resident investors, financial institutions, venture capital funds, public financial institutions, banks, multilateral and bilateral development financial institutions, insurance whether they be holders of equity shares of the Company or not, and / or through issue of offer documents ("Initial Public Offer") under (Issue of Capital and Disclosure Requirements) Regulations, 2018 of SEBI, through Book Building process, in one or more tranches and in the manner, and on the terms and conditions, as the Board may in its absolute sole discretion, decide including the price at which the equity shares are to be issued, at par or at premium and for cash and the decision to determine the category or categories of investors to whom the offer, issue and allotment / transfer shall be made to the exclusion of all other categories of investors on such terms and conditions as may be finalized by the Board and that the Board may finalize all matters incidental thereto as it may in its absolute discretion think fit;

**RESOLVED FURTHER THAT** all the Directors of the Company, be and are hereby severally authorized to make addition or vary any of the above said clauses, in consultation with the Book Running Lead Manager or such other authorities as may be required, and without prejudice to the generality of the aforesaid, deciding the exact Issue Structure, and on the exact component of fresh issue of shares in the Issue;

**RESOLVED FURTHER THAT**

- a) All the monies received out of the issue of shares to the public shall be transferred to separate bank account referred to in Sub-section (3) of Section 40 of the Companies Act, 2013;
- b) Details of all monies utilized out of the Issue referred to in sub-item (a) above shall be disclosed under an appropriate separate head in the balance sheet of the Company indicating the purpose for which such monies had been utilized; and
- c) Details of all unutilized monies out of the issue of shares, if any, referred to in sub-item (a) above shall be disclosed under an appropriate separate head in the balance sheet of the Company indicating the form in which such unutilized monies have been invested;

CIN No: U24230GJ2016PLC086559

PF-23 Sanand GIDC II, Sanand Ahmedabad-382110, Gujarat, India

Website: [www.curisls.com](http://www.curisls.com) | Email: [info@curisls.com](mailto:info@curisls.com) | Phone No: +91-7096558558



# Curis

Lifesciences Ltd.

- d) Object of the issue is Working Capital Requirement, General Corporate Purpose (GCP), Repayment of Loans (except repayment of loans owed to promoters, promoter group or related parties directly or indirectly), Investment in Subsidiaries, Capital Expenditure towards Expansion/Diversification, Various Marketing Initiatives, Public Issue Expense or any other object as may be decided by Board of Directors of the Company;

**RESOLVED FURTHER THAT** such of these equity shares to be issued as are not subscribed may be disposed of by the Board in favour of underwriter(s) to the issue;

**RESOLVED FURTHER THAT** any of the Directors of the Company, be and are hereby severally authorized to take such action, give such directions, as may be necessary or desirable to give effect to this resolution and to do all such acts, matters, deeds and things, including but not limited to the allotment of equity shares against the valid applications received in the Initial Public Offering, as are in the best interests of the Company;

**RESOLVED FURTHER THAT** any of the Directors of the Company, be and are hereby severally authorized to execute and sign the documents including consent letter, power of attorney, certificates etc., as may be required in connection with the above;

**RESOLVED FURTHER THAT** any of the Director of the Company be and are hereby severally authorized to appoint the Book Running Lead Manager to the above Issue;

**RESOLVED FURTHER THAT** any of the Director of the Company be and are hereby severally authorized to appoint the Registrar to the Issue;

**RESOLVED FURTHER THAT**

- a) The Company will furnish to the stock exchange on a quarterly / half yearly basis, a statement indicating material deviations, if any, in the use of proceeds of the Initial Public Offering from the objects stated in the Draft Red Herring Prospectus / Red Herring Prospectus/ Prospectus;

CIN No: U24230GJ2016PLC086559

PF-23 Sanand GIDC II, Sanand Ahmedabad-382110, Gujarat, India

Website: [www.curisls.com](http://www.curisls.com) | Email: [info@curisls.com](mailto:info@curisls.com) | Phone No: +91-7096558558



# Curis

Lifesciences Ltd.

- b) The information mentioned in sub-clause (a) shall be furnished to the stock exchange along with the interim or annual financial results submitted under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI (LODR), 2015) and shall be published in the newspapers, if required simultaneously with the interim or annual financial results, after placing it before the Audit Committee, in terms of Regulation 47 of SEBI (LODR), 2015;

**RESOLVED FURTHER THAT**, for the purpose of giving effect to these resolutions, any of the Directors of the Company be and are hereby severally authorized, on behalf of the Company, to decide and approve the terms and conditions of the Issue, including but not limited to reservations for employees or other permitted categories, and shall be entitled to vary, modify or alter any of the terms and conditions, including the size of the Issue, as it may consider expedient and to do all such acts, deeds, matters and things, as it may in its absolute sole discretion deem necessary, proper, desirable and to settle any question, difficulty or doubt that may arise in regard to the above offer, issue and allotment and utilization of the proceeds of the Issue, to liaise with regulatory authorities and further to do all such acts, deeds, matters and things and to negotiate and finalize all such deeds, documents and writings as may be necessary, desirable or expedient to give effect to the above resolution and to negotiate terms, appoint advisor(s), Book Running Lead Manager, registrar(s), syndicate member(s), underwriter(s) any other intermediary/intermediaries registered with SEBI, legal counsel or legal experts, advertising agents/agencies, consultants and to pay any fees, commission, remuneration, incur expenses and take such further steps as may be required necessary, incidental or ancillary for the allotment and listing of the aforesaid equity shares on the Stock Exchange (SME Segment) where the Company's equity shares are proposed to be listed, as may be decided by the Board, and to make such modifications without being required to seek further consents or approval of the members and that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution;

**RESOLVED FURTHER THAT** any of the Director of the Company be and are hereby severally authorized to do all the necessary acts and take necessary steps that may be deemed expedient to give effect to this resolution.

<<CERTIFIED TRUE COPY>>  
FOR CURIS LIFESCIENCES LIMITED

**DHARMESH DASHARATHBHAI PATEL**  
Managing Director  
DIN: 07371033  
Date: 15/05/2025  
Place: Ahmedabad



CIN No: U24230GJ2016PLC086559

PF-23 Sanand GIDC II, Sanand Ahmedabad-382110, Gujarat, India

Website: [www.curisls.com](http://www.curisls.com) | Email: [info@curisls.com](mailto:info@curisls.com) | Phone No: +91-7096558558